Immune checkpoint inhibitors (ICIs), including programmed cell death‐1 (PD‐1) inhibitor and programmed cell death ligand‐1 (PD‐L1) inhibitor, have become a standard treatment for patients with unresectable advanced or recurrent non‐small cell lung cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.